0001125345-24-000007.txt : 20240207
0001125345-24-000007.hdr.sgml : 20240207
20240207161712
ACCESSION NUMBER: 0001125345-24-000007
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240205
FILED AS OF DATE: 20240207
DATE AS OF CHANGE: 20240207
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Peters Jeffrey Stuart
CENTRAL INDEX KEY: 0001706903
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36112
FILM NUMBER: 24604537
MAIL ADDRESS:
STREET 1: 9704 MEDICAL CENTER DRIVE
CITY: ROCKVILLE
STATE: MD
ZIP: 20850
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: MACROGENICS INC
CENTRAL INDEX KEY: 0001125345
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 9704 MEDICAL CENTER DRIVE
CITY: Rockville
STATE: MD
ZIP: 20850
BUSINESS PHONE: 301-251-5172
MAIL ADDRESS:
STREET 1: 9704 MEDICAL CENTER DRIVE
CITY: ROCKVILLE
STATE: MD
ZIP: 20850
4
1
wk-form4_1707340620.xml
FORM 4
X0508
4
2024-02-05
0
0001125345
MACROGENICS INC
MGNX
0001706903
Peters Jeffrey Stuart
9704 MEDICAL CENTER DRIVE
ROCKVILLE
MD
20850
0
1
0
0
Senior VP and General Counsel
1
Common Stock
2024-02-05
4
M
0
54376
11.50
A
54376
D
Common Stock
2024-02-05
4
M
0
21875
10.15
A
76251
D
Common Stock
2024-02-05
4
S
0
54376
16.50
D
21875
D
Common Stock
2024-02-05
4
S
0
21875
16.50
D
0
D
Employee stock option (right to buy)
11.50
2024-02-05
4
M
0
54376
0
D
2030-02-20
Common Stock
54376
10875
D
Employee stock option (right to buy)
10.15
2024-02-05
4
M
0
21875
0
D
2032-02-22
Common Stock
21875
48125
D
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 11/10/2022.
12.5% of the shares underlying the grant became exercisable 6 months after the date of grant and an additional 6.25% of the shares underlying the grant became exercisable on the first day of each three-month period thereafter.
/s/ Lynn M. Cilinski, Attorney-in-fact
2024-02-07